Comerica Bank Sells 6,317 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

Comerica Bank trimmed its stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 7.4% during the fourth quarter, Holdings Channel reports. The firm owned 79,460 shares of the life sciences company’s stock after selling 6,317 shares during the period. Comerica Bank’s holdings in Integra LifeSciences were worth $1,802,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of IART. Norges Bank bought a new stake in Integra LifeSciences in the fourth quarter valued at $8,967,000. Principal Financial Group Inc. lifted its holdings in Integra LifeSciences by 5.5% during the 4th quarter. Principal Financial Group Inc. now owns 423,432 shares of the life sciences company’s stock valued at $9,603,000 after purchasing an additional 22,000 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its position in Integra LifeSciences by 7.1% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 13,756 shares of the life sciences company’s stock valued at $312,000 after buying an additional 913 shares in the last quarter. Nisa Investment Advisors LLC grew its stake in Integra LifeSciences by 599.6% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company’s stock worth $74,000 after buying an additional 2,800 shares during the last quarter. Finally, PNC Financial Services Group Inc. raised its stake in shares of Integra LifeSciences by 33.6% in the fourth quarter. PNC Financial Services Group Inc. now owns 19,755 shares of the life sciences company’s stock valued at $448,000 after acquiring an additional 4,967 shares during the last quarter. 84.78% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

IART has been the subject of a number of recent analyst reports. Wells Fargo & Company dropped their price target on Integra LifeSciences from $25.00 to $13.00 and set an “equal weight” rating for the company in a report on Tuesday. Truist Financial lowered their price objective on shares of Integra LifeSciences from $26.00 to $19.00 and set a “hold” rating for the company in a research report on Friday, April 11th. JPMorgan Chase & Co. decreased their price target on shares of Integra LifeSciences from $24.00 to $12.00 and set an “underweight” rating on the stock in a research note on Tuesday. Argus upgraded Integra LifeSciences from a “hold” rating to a “buy” rating in a research report on Monday, March 31st. Finally, JMP Securities cut their price target on Integra LifeSciences from $35.00 to $25.00 and set a “market outperform” rating on the stock in a research note on Friday. Four investment analysts have rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, Integra LifeSciences currently has a consensus rating of “Hold” and an average price target of $18.63.

Integra LifeSciences Stock Down 5.0 %

Shares of NASDAQ IART opened at $12.25 on Friday. The firm has a 50 day moving average price of $18.93 and a 200 day moving average price of $21.87. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. The stock has a market cap of $946.31 million, a P/E ratio of -136.10, a P/E/G ratio of 0.73 and a beta of 1.27. Integra LifeSciences Holdings Co. has a 52-week low of $11.60 and a 52-week high of $32.66.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings data on Monday, May 5th. The life sciences company reported $0.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.43 by ($0.02). Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The business had revenue of $382.65 million during the quarter, compared to analyst estimates of $381.17 million. During the same quarter in the prior year, the firm posted $0.55 earnings per share. Integra LifeSciences’s revenue for the quarter was up 3.7% compared to the same quarter last year. Analysts expect that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.